Novo Nordisk stock (DK0062498333): Wegovy pressure, U.S. demand and the next catalyst

Novo Nordisk enters a new stretch of scrutiny as U.S. obesity-drug demand, competition and pricing debates stay in focus for investors.

Novo Nordisk is back in the spotlight as the obesity-drug market remains one of the most closely watched themes for U.S. investors. The Danish drugmaker’s weight-loss and diabetes portfolio continues to shape sentiment around the stock, with attention centered on U.S. demand, competition from rival GLP-1 treatments and the pace of supply expansion.

In its most recent annual report, Novo Nordisk said 2024 sales rose 26% at constant exchange rates and operating profit increased 25%, underscoring how strongly the company remains tied to its diabetes and obesity franchises. For U.S. investors, that makes the shares a direct play on prescription-drug spending, insurer access and the broader GLP-1 category, according to Novo Nordisk Annual Report 2024 as of 02/05/2026.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novo Nordisk A/S
• Sector/industry: Pharmaceuticals / obesity and diabetes treatments
• Headquarters/country: Denmark
• Core markets: United States, Europe, international markets
• Key revenue drivers: Diabetes, obesity and related chronic-care medicines
• Home exchange/listing venue: Nasdaq Copenhagen; ADRs trade in the U.S.
• Trading currency: Danish krone; U.S. dollar for ADR trading

Novo Nordisk: core business model

Novo Nordisk develops and sells medicines for diabetes, obesity and other chronic diseases, with GLP-1 therapies at the center of the company’s market value. The business model is driven by prescription volume, reimbursement access and manufacturing capacity, all of which matter more when demand rises quickly in the U.S. market.

The company’s latest annual filing showed that its growth still comes mainly from diabetes and obesity products, which remained the largest contributors to revenue. That concentration gives the stock a clear operating lever, but it also leaves investors exposed to competition, pricing pressure and policy changes affecting U.S. drug spending, according to Novo Nordisk Annual Report 2024 as of 02/05/2026.

Main revenue and product drivers for Novo Nordisk

Wegovy and Ozempic are the best-known commercial drivers in the company’s portfolio, while insulin and rare-disease treatments still provide an important base. The key question for investors is how fast Novo Nordisk can scale supply and maintain access as the obesity market expands and competitors push harder.

That dynamic is especially relevant in the United States, where insurance coverage, pharmacy access and employer benefit decisions can change demand quickly. The company’s U.S. exposure is also one reason the stock often reacts to headlines about pricing, Medicare negotiations and rival drug launches, even when the original news does not come from Novo Nordisk itself.

Novo Nordisk said in its 2024 report that the obesity segment remained a major driver of group performance, and management highlighted continued investment in production capacity and pipeline development. For market participants, that makes execution on supply, clinical data and label expansion central to the next phase of the story.

Why Novo Nordisk matters for US investors

Novo Nordisk matters to U.S. investors because its most important commercial battleground is the American healthcare system. The company’s obesity business is tied to prescription trends, insurance access and employer coverage, making it one of the clearest non-U.S. plays on the U.S. weight-loss boom.

The shares also function as a sentiment gauge for the wider GLP-1 trade, which has implications for healthcare ETFs, pharma competitors and suppliers across the U.S. market. When investors reassess demand or pricing assumptions for Novo Nordisk, they often do the same for the broader obesity-drug category.

Risks and open questions

The main risks are familiar: competition, manufacturing bottlenecks, pricing pressure and the possibility that growth normalizes as the market matures. Any shift in reimbursement policy or safety perception could affect U.S. prescriptions, and that would likely show up quickly in the stock.

Another open question is how long Novo Nordisk can sustain the high expectations built into the obesity narrative. The business remains strong, but the valuation debate tends to move with every update on capacity, pipeline progress or market-share changes.

Conclusion

Novo Nordisk remains one of the most closely watched healthcare stocks for U.S. investors because its business is tied to a major American prescription trend. The company’s latest annual results showed continued revenue and profit growth, but the market still wants proof that supply, access and competitive positioning can keep pace. That combination keeps the stock in a sensitive zone where fundamental progress and sentiment can diverge quickly.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.